Trifluridine and Tipiracil Tablets

DRUG3 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shandong New Time Pharmaceutical Co., LTD, Shanghai Zhongshan Hospital

Conditions

Colorectal CancerColorectal NeoplasmsSolid Tumor Cancer

Phase 1

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

CompletedNCT03974594

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Colorectal Cancer

Start: 2019-05-21End: 2019-07-16Updated: 2022-04-19

Phase 2

SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer

Not yet recruitingNCT07535632

Shanghai Zhongshan HospitalColorectal Neoplasms

Start: 2026-06-01End: 2028-06-01Target: 58Updated: 2026-04-17

Unknown Phase

Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans

CompletedNCT07492173

Shandong New Time Pharmaceutical Co., LTDSolid Tumor Cancer

Start: 2022-11-21End: 2023-06-25Updated: 2026-03-25